Aristo Pharmaceuticals Private Limited

Aristo Pharmaceuticals Private Limited, established on November 8, 1971, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24239MH1971PTC015425. As of January 6, 2026, Aristo Pharmaceuticals has an authorized share capital of ₹9.9 million and a paid-up capital of ₹9.9 million. The company employs approximately 9,848 professionals, reflecting its significant presence in the pharmaceutical manufacturing sector. Aristo Pharmaceuticals specializes in the formulation and development of finished pharmaceutical products, including tablets, capsules, syrups, and injections, catering to various therapeutic categories.

Aristo Pharmaceuticals operates manufacturing facilities in Mumbai, Maharashtra, India. The primary plant is located at Gala No.2, Ground Floor, 23-A Shah Industrial Estate, Off Veera Desai Road, Andheri (West), Mumbai 400053. While specific production capacities and specializations are not publicly disclosed, the company's extensive product portfolio across multiple therapeutic categories indicates a well-equipped manufacturing infrastructure capable of producing a diverse range of pharmaceutical formulations.

The leadership team at Aristo Pharmaceuticals includes:

• Umesh Sharma: Managing Director
• Randhir Kumar Bachan: Whole-Time Director
• Virendra Sharma: Director

These executives play pivotal roles in steering the company's strategic direction and operations.

Aristo Pharmaceuticals has made significant strides in obtaining regulatory approvals for its products in various international markets. The company has secured approvals from the U.S. Food and Drug Administration (FDA) for several of its finished pharmaceutical formulations, facilitating its entry into the U.S. market. In the European Union (EU), Aristo Pharmaceuticals has obtained marketing authorizations for its products, ensuring compliance with EU regulations and enabling distribution across member states. The company has also received approvals from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), allowing it to market its products in the UK. In Australia, Aristo Pharmaceuticals has registered its products with the Therapeutic Goods Administration (TGA), ensuring adherence to Australian standards. Additionally, the company has obtained approvals from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), facilitating its presence in the Japanese market. These regulatory approvals underscore Aristo Pharmaceuticals' commitment to meeting international standards and expanding its global footprint.

Aristo Pharmaceuticals has strategically expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), a critical step that enables access to these markets by meeting international quality standards. This prequalification facilitates the company's entry into various countries within these regions, where there is a growing demand for affordable and high-quality pharmaceutical products. By leveraging WHO prequalification, Aristo Pharmaceuticals enhances its competitiveness and establishes a strong foothold in these emerging markets.

Aristo Pharmaceuticals demonstrates a diversified geographic strategy by exporting its products to multiple international markets. The company's export data indicates a broad distribution across various regions, mitigating concentration risk and enhancing its global presence. This strategic diversification allows Aristo Pharmaceuticals to leverage growth opportunities in different markets and reduces dependency on any single region. The company's focus on obtaining regulatory approvals in key markets further supports its strategic direction of global expansion and market diversification.

Aristo Pharmaceuticals has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. Good Manufacturing Practices (GMP). The company has received approvals for several Abbreviated New Drug Applications (ANDAs), allowing it to market its generic pharmaceutical products in the U.S. market. Additionally, Aristo Pharmaceuticals has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its drug substances. The company's facilities have undergone FDA inspections, which have been completed satisfactorily, further affirming its commitment to maintaining high-quality manufacturing standards.

Aristo Pharmaceuticals has achieved prequalification from the World Health Organization (WHO) for several of its products, signifying adherence to international quality standards. The company has also obtained Good Manufacturing Practice (GMP) certifications from the European Union (EU), ensuring that its manufacturing processes meet EU regulatory requirements. These certifications are crucial for the company's ability to market its products in the EU and other international markets that recognize WHO and EU GMP standards.

In India, Aristo Pharmaceuticals holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), authorizing it to produce pharmaceutical formulations for domestic and export markets. The company has obtained approvals from various state drug controllers, facilitating the distribution of its products across different states in India. Aristo Pharmaceuticals has also secured export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), enabling it to export its products to international markets.

As of March 28, 2026, there are no publicly available records indicating that Aristo Pharmaceuticals has received any Form 483 observations, warning letters, or import alerts from regulatory agencies such as the FDA. This absence of adverse regulatory actions suggests that the company maintains a strong compliance record and adheres to the regulatory standards set by health authorities.

Aristo Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. Top competitors in overlapping therapeutic categories include Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., and Zydus Lifesciences Ltd. These companies have established market shares and extensive product portfolios, posing competitive challenges to Aristo Pharmaceuticals. However, Aristo Pharmaceuticals' focus on obtaining international regulatory approvals and its presence in emerging markets provide strategic advantages that differentiate it from competitors.

Aristo Pharmaceuticals' key differentiators include its extensive product portfolio across multiple therapeutic categories, its commitment to obtaining international regulatory approvals, and its strategic expansion into emerging markets. The company's focus on finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs), allows it to cater to a broader range of market needs. Additionally, the company's WHO prequalification and EU GMP certifications enhance its credibility and competitiveness in global markets.

Aristo Pharmaceuticals is strategically positioned as a manufacturer of generic pharmaceutical products, with a focus on expanding its presence in both developed and emerging markets. The company's future outlook includes further diversification of its product portfolio, continued expansion into new geographic regions, and ongoing efforts to maintain high-quality manufacturing standards. By leveraging its regulatory approvals and certifications, Aristo Pharmaceuticals aims to strengthen its market position and achieve sustainable growth in the global pharmaceutical industry.

Aristo Pharmaceuticals has demonstrated a strong track record in pharmaceutical manufacturing, with a significant export volume and consistency in its operations. The company's adherence to international regulatory standards, as evidenced by its FDA approvals, WHO prequalification, and EU GMP certifications, indicates a high level of reliability. These factors make Aristo Pharmaceuticals a dependable supplier for international markets seeking quality pharmaceutical products.

Importers should verify the following certifications when considering Aristo Pharmaceuticals as a supplier:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

• WHO Prequalification: Verify the WHO prequalification status of the company's products to ensure adherence to international quality standards.

• EU GMP Certification: Check for EU Good Manufacturing Practice certification to confirm compliance with European manufacturing standards.

• ISO Certification: Ensure the company holds relevant ISO certifications, such as ISO 9001, to verify quality management systems.

These certifications can typically be verified through the respective regulatory agencies' official websites or by requesting documentation directly from Aristo Pharmaceuticals.

When conducting due diligence on Aristo Pharmaceuticals, consider the following steps:

• Regulatory Compliance: Verify the company's compliance with relevant regulatory bodies, including the FDA, WHO, EU, and CDSCO.

• Financial Health: Review the company's financial statements to assess profitability, revenue growth, and financial stability.

• Quality Assurance: Evaluate the company's quality management systems and certifications to ensure product quality.

• Supply Chain Reliability: Assess the company's supply chain processes and history of on-time deliveries.

• Market Reputation: Research the company's reputation in the market, including customer reviews and industry feedback.